Latest news with #MedAdvisorLimited
Business Insider
13-05-2025
- Business
- Business Insider
MedAdvisor Limited (MDR) Gets a Hold from MA Financial Group
In a report released on May 9, Sarah Mann from MA Financial Group maintained a Hold rating on MedAdvisor Limited (MDR – Research Report), with a price target of A$0.11. The company's shares closed yesterday at A$0.10. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Mann is ranked #3918 out of 9492 analysts. Currently, the analyst consensus on MedAdvisor Limited is a Hold with an average price target of A$0.13, implying a 35.42% upside from current levels. In a report released today, Bell Potter also maintained a Hold rating on the stock with a A$0.10 price target. The company has a one-year high of A$0.59 and a one-year low of A$0.08. Currently, MedAdvisor Limited has an average volume of 717K.
Yahoo
20-02-2025
- Business
- Yahoo
Is It Too Late To Consider Buying MedAdvisor Limited (ASX:MDR)?
While MedAdvisor Limited (ASX:MDR) might not have the largest market cap around , it received a lot of attention from a substantial price movement on the ASX over the last few months, increasing to AU$0.33 at one point, and dropping to the lows of AU$0.16. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether MedAdvisor's current trading price of AU$0.17 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at MedAdvisor's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Check out our latest analysis for MedAdvisor According to our valuation model, MedAdvisor seems to be fairly priced at around 12% below our intrinsic value, which means if you buy MedAdvisor today, you'd be paying a fair price for it. And if you believe that the stock is really worth A$0.19, then there's not much of an upside to gain from mispricing. In addition to this, MedAdvisor has a low beta, which suggests its share price is less volatile than the wider market. Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. MedAdvisor's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value. Are you a shareholder? It seems like the market has already priced in MDR's positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you've been keeping an eye on MDR, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. If you'd like to know more about MedAdvisor as a business, it's important to be aware of any risks it's facing. At Simply Wall St, we found 1 warning sign for MedAdvisor and we think they deserve your attention. If you are no longer interested in MedAdvisor, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
